寡进展局部消融 + 奥希替尼再挑战：前瞻性 II 期研究
类型: II期临床试验 / 局部治疗 发表日期: 2025-08-06 入库日期: 2026-05-21 来源: PubMed / JTO Clinical and Research Reports 标签: EGFR L858R, 奥希替尼, 寡进展, 局部治疗, 放疗, 再挑战
Citation
Local Ablative Therapy Followed by Osimertinib Rechallenge in Oligoprogressive, EGFR-Mutated NSCLC: A Phase 2 Study. JTO Clinical and Research Reports. 2025. PMID: 41018053. DOI: 10.1016/j.jtocrr.2025.100886
Why it matters for mom
Mom had a notable sternum/parasternal soft-tissue lesion while other disease areas were more stable or mixed. If doctors judge this as oligoprogression rather than broad systemic failure, local therapy while continuing EGFR control can be a rational discussion.
Practical takeaways
- This applies only when progression is limited to a small number of lesions and systemic control is otherwise acceptable.
- Local therapy can be radiation, surgery, ablation, or other site-specific treatment depending on anatomy.
- The decision should integrate pain, fracture risk, biopsy value, and whether the lesion is safely targetable.
Questions for doctors
- Is the sternum/soft-tissue lesion oligoprogressive disease or part of diffuse progression?
- Could the lesion be both biopsied and locally treated?
- Would local treatment allow continuing the current systemic backbone longer?